Référentiel des médicaments
Galcanezumab
Galcanezumab is a medicine in the class central nervous system. It is used for cluster headache.
- Classe médicamenteuse: Central Nervous System
- Indications: cluster headache
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Central Nervous System
- Formes courantes
- injection
- Dosages courants
- 120 mg/ml, 100 mg/ml
- Interactions connues
- 3 (Modérée: 3)
- Noms commerciaux
- 5
- Pays et marchés
- 5
Indications
Mécanisme d'action
Humanized monoclonal antibody; binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor
Posologie adulte habituelle (résumé de la notice)
Migraine Prophylaxis: Loading dose: 240 mg SC once (ie, 2 consecutive 120-mg SC injections), Maintenance dose: 120 mg SC monthly
Grossesse et allaitement
- Grossesse
- Unknown No adequate human data; no harm in rat and rabbit studies. As an IgG antibody it crosses the placenta, mainly late in pregnancy, and exposure continues for months after the last dose; a pregnancy registry exists. EU label: as a precaution, preferable to avoid in pregnancy.
- Allaitement
- Unknown No milk data. EU label: a risk cannot be excluded in the first days after birth; afterwards use only if clinically needed. LactMed: likely very low in milk and partly digested by the infant; use with caution, especially with a newborn or preterm infant.
Effets indésirables signalés
- Injection site reactions
- Angioedema
Contre-indications
- Serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Précautions particulières
- Hypersensitivity reactions (dyspnea, urticaria, rash; anaphylaxis and angioedema postmarketing) can occur, even days after administration, and may be prolonged. If a serious reaction occurs, discontinue and treat appropriately.
- Constipation with serious complications, including hospitalization and surgery, has been reported, usually after the first dose. Monitor for severe constipation; medications that reduce GI motility may increase the risk.
- New-onset or worsening hypertension has been reported, most often within 7 days of starting. Monitor blood pressure and consider discontinuation if no other cause is found or BP is inadequately controlled.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (3)
- Efgartigimod / hyaluronidase sc + Galcanezumab Moderate
- Efgartigimod alfa + Galcanezumab Moderate
- Galcanezumab + Rozanolixizumab Moderate
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Galcanezumab : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Galcanezumab used for?
Galcanezumab is a medicine in the class central nervous system. It is used for Cluster headache, Migraine.
What side effects have been reported with Galcanezumab?
Injection site reactions, Angioedema.
Can Galcanezumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. No adequate human data; no harm in rat and rabbit studies. As an IgG antibody it crosses the placenta, mainly late in pregnancy, and exposure continues for months after the last dose; a pregnancy registry exists. EU label: as a precaution, preferable to avoid in pregnancy. Breastfeeding: Unknown. No milk data. EU label: a risk cannot be excluded in the first days after birth; afterwards use only if clinically needed. LactMed: likely very low in milk and partly digested by the infant; use with caution, especially with a newborn or preterm infant.
What does Galcanezumab interact with?
MediHelp lists 3 known interactions for Galcanezumab. Moderate: 3. The most serious include Efgartigimod / hyaluronidase sc, Efgartigimod alfa, Rozanolixizumab.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
